Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Secondary Malignant Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Malignant Neoplasm
Secondary Malignant Neoplasm

Cancer Family

Secondary Malignant Neoplasm

CI-CAN-00000346SMNExplore in graph →

4,275 active trials56 approved drugs532 evidence items

NCIt: C4968

Overview
Statistics
Survival
Genomics199
Variants & evidence532
Drugs130
Trials14671
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (486)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 176–200 of 486 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan.
· Jpn J Clin Oncol · 1998 · PMID 9839497 · validated civic_curation pubmed
PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.
· Oncology · 2015 · PMID 25300346 · validated civic_curation pubmed
A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
· Clin Breast Cancer · 2015 · PMID 25537159 · validated civic_curation pubmed
p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas.
· Oral Oncol · 2014 · PMID 24239278 · validated civic_curation pubmed
Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.
· Br J Cancer · 2012 · PMID 22596232 · validated civic_curation pubmed
Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer.
· Int J Cancer · 2012 · PMID 22422354 · validated civic_curation pubmed
CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer.
· Anticancer Res · 2010 · PMID 20651371 · validated civic_curation

Showing 176–200 of 486 publications

← Previous
1
…
7
8
9
…
20
Next →

Correlation of basic fibroblast growth factor expression with the invasion and the prognosis of oral squamous cell carcinoma.

· J Oral Pathol Med · 2006 · PMID 16454808 · validated civic_curation pubmed

Mutation and methylation analysis of TP53 in adrenal carcinogenesis.

· Eur J Surg Oncol · 2005 · PMID 15922892 · validated civic_curation pubmed

Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes.

· Oncotarget · 2016 · PMID 26872370 · validated civic_curation pubmed

PSMB8 and PBK as potential gastric cancer subtype-specific biomarkers associated with prognosis.

· Oncotarget · 2016 · PMID 26894977 · validated civic_curation pubmed

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

· Lancet Oncol · 2015 · PMID 25892145 · validated civic_curation pubmed

High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.

· Oncotarget · 2016 · PMID 26950277 · validated civic_curation pubmed

Nuclear heat shock protein 110 expression is associated with poor prognosis and chemotherapy resistance in gastric cancer.

· Oncotarget · 2016 · PMID 26943774 · validated civic_curation pubmed

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

· Cancer Cell · 2007 · PMID 17936563 · validated civic_curation pubmed

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

· N Engl J Med · 2016 · PMID 27093365 · validated civic_curation pubmed

A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

· Clin Cancer Res · 2014 · PMID 25294897 · validated civic_curation pubmed

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

· Clin Cancer Res · 2013 · PMID 23881929 · validated civic_curation pubmed

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.

· J Thorac Oncol · 2016 · PMID 26773740 · validated civic_curation pubmed

Clinical correlation of extensive-stage small-cell lung cancer genomics.

· Ann Oncol · 2016 · PMID 26802149 · validated civic_curation pubmed

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.

· Nat Commun · 2016 · PMID 27302369 · validated civic_curation pubmed

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

· Clin Cancer Res · 2009 · PMID 19118063 · validated civic_curation pubmed

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).

· PLoS One · 2016 · PMID 27032107 · validated civic_curation pubmed

Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization.

· Mol Cell Endocrinol · 2015 · PMID 25448848 · validated civic_curation pubmed

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.

· J Clin Oncol · 2021 · PMID 33750196 · validated civic_curation pubmed